

# Tirzepatide Once Weekly for the Treatment of Obesity

New England Journal of Medicine

387, 205-216

DOI: [10.1056/nejmoa2206038](https://doi.org/10.1056/nejmoa2206038)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Shifting Tides Offer New Hope For Obesity. <i>New England Journal of Medicine</i> , 2022, 387, 271-273.	27.0	10
3	Diabetes drug results in substantial weight loss in people with obesity, study finds. <i>BMJ</i> , The, 0, , o1406.	6.0	0
5	Gut hormones and reproduction (Hormones intestinalis et reproduction). <i>Annales D'Endocrinologie</i> , 2022, , .	1.4	3
6	Tirzepatide highly effective for weight loss. <i>Nature Reviews Endocrinology</i> , 2022, 18, 520-520.	9.6	5
7	Tirzepatide to treat obesity: phase III results. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 488-488.	17.8	3
8	Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?. <i>Metabolism: Clinical and Experimental</i> , 2022, 136, 155248.	3.4	14
9	Editorial for "Effect of Obesity on Left Ventricular Remodeling and Clinical Outcome in Chinese Patients With Hypertrophic Cardiomyopathy Assessed by Cardiac Magnetic Resonance Imaging" <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 810-811.	3.4	0
10	Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. <i>Molecules</i> , 2022, 27, 4315.	3.8	56
11	Cardiovascular Disease Risk Reduction and Body Mass Index. <i>Current Hypertension Reports</i> , 2022, 24, 535-546.	3.5	6
12	Tirzepatide: First Approval. <i>Drugs</i> , 2022, 82, 1213-1220.	10.9	41
13	<scp>Glucagon-like peptide</scp>-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor polyagonists: a new era in obesity pharmacotherapy. <i>Obesity</i> , 2022, 30, 1718-1721.	3.0	4
14	Less weight, less cancer? The potential positive effects of bariatric surgery beyond cardiovascular risk reduction. <i>European Heart Journal</i> , 0, , .	2.2	0
15	Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects. <i>European Heart Journal</i> , 0, , .	2.2	2
16	Non-pharmacologic treatment for obesity. <i>Journal of the Korean Medical Association</i> , 2022, 65, 400-407.	0.3	0
17	Pharmacologic treatment of obesity. <i>Journal of the Korean Medical Association</i> , 2022, 65, 408-416.	0.3	0
18	The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. <i>Nature Reviews Endocrinology</i> , 2022, 18, 623-637.	9.6	32
19	Insulin sensitive human adipocytes for in vitro studies. <i>Nature Reviews Endocrinology</i> , 2022, 18, 591-592.	9.6	1
20	Next Step in Incretin-Based Therapy: From Single to Dual Agonism. <i>European Medical Journal Diabetes</i> , 0, , .	4.0	1

#	ARTICLE	IF	CITATIONS
21	Endoscopic sleeve gastropasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. <i>Lancet, The</i> , 2022, 400, 441-451.	13.7	102
22	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4051.	3.7	11
23	Pharmacotherapy in obesity: the current state and the near future. <i>Journal of the Korean Medical Association</i> , 2022, 65, 514-531.	0.3	0
24	Revisional Surgery or Pharmacotherapy for Insufficient Weight Loss and Weight Regain After Primary Bariatric Procedure: a Descriptive Study. <i>Obesity Surgery</i> , 2022, 32, 3298-3304.	2.1	7
25	Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-17.	4.4	36
26	Management of <sc>NAFLD</sc> in primary care settings. <i>Liver International</i> , 2022, 42, 2377-2389.	3.9	31
27	Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide. <i>American Journal of Cardiology</i> , 2022, 181, 139-140.	1.6	11
28	Derivatization with fatty acids in peptide and protein drug discovery. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 59-80.	46.4	19
31	Who knew? PPARs may act in the brain too. <i>Nature Metabolism</i> , 2022, 4, 965-966.	11.9	0
32	DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. <i>Military Medical Research</i> , 2022, 9, .	3.4	4
33	Reframing the need for exercise therapy in the clinical management of people living with obesity. <i>Clinical Obesity</i> , 2022, 12, .	2.0	0
34	Toward a new model for the management of type 2 diabetes: The mountain is there and there is no other option than to climb it. <i>Pharmacological Research</i> , 2022, 184, 106443.	7.1	4
35	Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity. <i>Journal of General Internal Medicine</i> , 0, , .	2.6	1
36	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2022, 65, 1925-1966.	6.3	273
37	Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 955-964.	2.0	4
38	The potential of glucagon-like peptide-1 receptor agonists in heart failure. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	3
39	Integrated Care Model of Adiposity-Related Chronic Diseases. <i>Current Hypertension Reports</i> , 0, , .	3.5	0
40	Extent of Role: Anti-Diabetic Medications. <i>Journal of Korean Diabetes</i> , 2022, 23, 153-156.	0.3	0

#	ARTICLE	IF	CITATIONS
41	Long-Term Results at 10 Years of Pouch Resizing for Roux-en-Y Gastric Bypass Failure. <i>Nutrients</i> , 2022, 14, 4035.	4.1	2
42	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2022, 45, 2753-2786.	8.6	435
43	Obesity in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, .	4.5	5
45	Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	4
46	Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. <i>Nutrients</i> , 2022, 14, 3775.	4.1	2
47	Editorial: Hungry for more: What's new in appetite regulation. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, , 100417.	1.4	0
48	Tirzepatide. <i>Hospital Pharmacy</i> , 2023, 58, 227-243.	1.0	3
49	New Horizons: Emerging Antidiabetic Medications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4333-e4340.	3.6	6
50	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	79
51	New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 522-528.	2.6	7
52	Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial. <i>Obesity</i> , 2022, 30, 2222-2232.	3.0	7
54	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. <i>Obesity Medicine</i> , 2022, 35, 100456.	0.9	8
55	Addressing insurance-related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery. <i>Obesity</i> , 2022, 30, 2338-2339.	3.0	4
56	Obesity and diabetes in people of African ancestry with <sc>HIV</sc>. <i>HIV Medicine</i> , 2023, 24, 380-388.	2.2	2
57	Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. <i>Journal of Diabetes and Its Complications</i> , 2022, , 108332.	2.3	6
59	A Pathophysiological Intersection of Diabetes and Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11562.	4.1	6
60	The Novel Peptide Chm-273s Has Therapeutic Potential for Metabolic Disorders: Evidence from In Vitro Studies and High-Sucrose Diet and High-Fat Diet Rodent Models. <i>Pharmaceutics</i> , 2022, 14, 2088.	4.5	1
61	Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. <i>World Journal of Gastroenterology</i> , 0, 28, 5691-5706.	3.3	7

#	ARTICLE	IF	CITATIONS
62	Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin. <i>Life</i> , 2022, 12, 1663.	2.4	8
63	Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in <i>Caenorhabditis elegans</i> : A systematic review and meta-analysis. <i>Aging Cell</i> , 2022, 21, .	6.7	5
65	LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. <i>Lancet, The</i> , 2022, 400, 1869-1881.	13.7	78
67	Tirzepatide Once Weekly for the Treatment of Obesity. <i>New England Journal of Medicine</i> , 2022, 387, 1433-1435.	27.0	5
68	Harnessing the Incretin System with Multi-Agonists. <i>European Medical Journal Innovations</i> , 0, , .	2.0	1
69	Semaglutide for the treatment of overweight and obesity: A review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 18-35.	4.4	26
70	Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs). , 2022, 4, 100039.		6
71	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	21
72	The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans. <i>Endocrine Reviews</i> , 2023, 44, 281-296.	20.1	9
74	New research on treating obesity through medical and behavioural intervention. <i>Journal of Prescribing Practice</i> , 2022, 4, 424-425.	0.1	0
75	Tirzepatide—Friend or Foe in Diabetic Cancer Patients?. <i>Biomolecules</i> , 2022, 12, 1580.	4.0	4
76	Treating inflammation to combat non-alcoholic fatty liver disease. <i>Journal of Endocrinology</i> , 2023, 256, .	2.6	21
77	Type 2 diabetes. <i>Lancet, The</i> , 2022, 400, 1803-1820.	13.7	176
79	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. <i>Gastroenterology</i> , 2022, 163, 1198-1225.	1.3	39
80	Obesity and asthma: A focused review. <i>Respiratory Medicine</i> , 2022, 204, 107012.	2.9	3
82	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. <i>Biochemical Pharmacology</i> , 2022, 206, 115304.	4.4	5
83	The treatment of diabetes in advanced liver disease: change of a paradigm. <i>Annals of Hepatology</i> , 2023, 28, 100772.	1.5	4
84	Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. <i>Annals of Pharmacotherapy</i> , 2023, 57, 822-836.	1.9	5

#	ARTICLE	IF	CITATIONS
85	The Anti-Inflammatory Effect of Novel Antidiabetic Agents. <i>Life</i> , 2022, 12, 1829.	2.4	9
88	Update on technologies, medicines and treatments. <i>Diabetic Medicine</i> , 0, , .	2.3	0
89	Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma. <i>Clinical and Experimental Allergy</i> , 2023, 53, 216-221.	2.9	1
90	Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches. <i>Nutrients</i> , 2022, 14, 4801.	4.1	5
92	Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist. <i>Journal for Nurse Practitioners</i> , 2023, 19, 104474.	0.8	0
93	Tirzepatide: Revolutionary Drug in Management of "Diabetes". <i>International Journal of Medical and Dental Sciences</i> , 0, , 2046-2050.	0.1	0
95	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 40-53.	1.0	0
96	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease"Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> . 2022. 27. 107424842211463.	2.0	15
97	Obesity pharmacotherapy: incretin action in the central nervous system. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 50-63.	8.7	10
98	Corrigendum to "Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes" [Biochem. Pharmacol. 206 (2022) 115304]. <i>Biochemical Pharmacology</i> , 2023, 207, 115349.	4.4	0
100	Treating chronic diseases without tackling excess adiposity promotes multimorbidity. <i>Lancet Diabetes and Endocrinology</i> , 2023, 11, 58-62.	11.4	16
101	Why Are Cardiologists Not Prescribing the New Diabetes Medications?. <i>American Journal of Cardiology</i> , 2023, 187, 74-75.	1.6	1
102	Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes. <i>Peptides</i> , 2023, 160, 170923.	2.4	8
103	Combining metabolic surgery with medications for type 2 diabetes: Is there a benefit?. , 2022, .		0
104	Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution. <i>Transplantation</i> , 2023, 107, 1021-1022.	1.0	0
105	Gut "hormone triple agonists: clinical safety and metabolic benefits. <i>Lancet, The</i> , 2022, 400, 1826-1828.	13.7	4
106	Diabetes in HIV: the Link to Weight Gain. <i>Current HIV/AIDS Reports</i> , 2023, 20, 9-18.	3.1	5
107	Hypoxia as a Double-Edged Sword to Combat Obesity and Comorbidities. <i>Cells</i> , 2022, 11, 3735.	4.1	10

#	ARTICLE	IF	CITATIONS
108	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. <i>Nature Reviews Endocrinology</i> , 2023, 19, 151-163.	9.6	21
109	New therapies for obesity. <i>Cardiovascular Research</i> , 2024, 119, 2825-2842.	3.8	16
110	Tirzepatide: A Systematic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14631.	4.1	12
111	Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction. <i>Nature Metabolism</i> , 2022, 4, 1495-1513.	11.9	9
112	Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. <i>Nature Reviews Endocrinology</i> , 2023, 19, 201-216.	9.6	44
114	Tirzepatide and prevention of chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 797-808.	2.9	10
115	Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist 456906. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1011-1023.	4.4	21
118	Tirzepatide (Mounjaro): A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus. <i>American Journal of Therapeutics</i> , 0, Publish Ahead of Print, .	0.9	3
119	Prevention of cardiorenal damage: importance of albuminuria. <i>European Heart Journal</i> , 2023, 44, 1112-1123.	2.2	12
120	Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. <i>Obesity</i> , 2023, 31, 96-110.	3.0	22
121	The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. <i>Metabolism Open</i> , 2022, 16, 100220.	2.9	6
122	Co-agonist therapeutics come of age for obesity. <i>Nature Reviews Endocrinology</i> , 2023, 19, 66-67.	9.6	5
123	Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. , 2022, 4, 100048.		7
124	Endocrinologie, un nouveau traitement de l'obésité chronique. <i>Revue Francophone Des Laboratoires</i> , 2022, 2022, 17.	0.0	0
126	3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes 2023. <i>Diabetes Care</i> , 2023, 46, S41-S48.	8.6	55
127	An inflection point in global public health. <i>Globalization and Health</i> , 2022, 18, .	4.9	3
128	Weight-centric treatment of type 2 diabetes mellitus. , 2022, 4, 100045.		13
130	NAFLD, MAFLD and obesity: brothers in arms?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 67-68.	17.8	12

#	ARTICLE	IF	CITATIONS
131	Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 961-964.	4.4	7
133	5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes 2023. <i>Diabetes Care</i> , 2023, 46, S68-S96.	8.6	124
134	Brain-to-BAT - and Back?: Crosstalk between the Central Nervous System and Thermogenic Adipose Tissue in Development and Therapy of Obesity. <i>Brain Sciences</i> , 2022, 12, 1646.	2.3	3
135	Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2023, 30, 1-6.	2.3	1
136	Targeting inflammation to treat diabetic kidney disease: the road to 2030. <i>Kidney International</i> , 2023, 103, 282-296.	5.2	32
137	The “breakthrough” obesity drugs that have stunned researchers. <i>Nature</i> , 2023, 613, 16-18.	27.8	6
138	Pharmacologic management of weight regain following bariatric surgery. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	7
139	Management of metabolic-associated fatty liver disease: The diabetology perspective. <i>World Journal of Gastroenterology</i> , 0, 29, 126-143.	3.3	12
140	Obesity and diabetes: the final frontier. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 81-94.	2.4	4
141	GLP-1R Signaling and Functional Molecules in Incretin Therapy. <i>Molecules</i> , 2023, 28, 751.	3.8	7
142	An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	5
143	Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
144	A critical update on the leptin-melanocortin system. <i>Journal of Neurochemistry</i> , 2023, 165, 467-486.	3.9	5
145	Brave New World: Improving Obesity and Preventing Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2023, 98, 11-14.	3.0	0
146	Metabolic Messengers: glucagon. <i>Nature Metabolism</i> , 2023, 5, 186-192.	11.9	9
147	HIV and obesity: updates in management strategies. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 68-74.	3.8	3
148	Compliance to Multidisciplinary Lifestyle Intervention Decreases Blood Pressure in Patients with Resistant Hypertension: A Cross-Sectional Pilot Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 679.	2.4	3
149	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108389.	2.3	7



#	ARTICLE	IF	CITATIONS
150	Effect of tirzepatide on prediabetics and blood pressure with implications for future research. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2023, 34, 243-244.	1.3	0
151	Obesity-related kidney disease: Beyond hypertension and insulin-resistance. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	14
152	The naturally occurring GIP(1-30)NH <sub>2</sub> is a GIP receptor agonist in humans. <i>European Journal of Endocrinology</i> , 2023, 188, 48-58.	3.7	0
153	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2023, 43, 1-7.	2.1	3
154	Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. <i>Annales D'Endocrinologie</i> , 2023, 84, 316-321.	1.4	15
155	Is bariatric surgery safer before, during, or after liver transplantation? A systematic review and meta-analysis. <i>Journal of Liver Transplantation</i> , 2023, 9, 100139.	0.4	3
156	Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 179-191.	8.1	28
157	An update on peptide-based therapies for type 2 diabetes and obesity. <i>Peptides</i> , 2023, 161, 170939.	2.4	34
158	Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery. , 2022, 1, .		0
159	Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. <i>Obesity Reviews</i> , 2023, 24, .	6.5	19
160	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4449-4461.	4.3	8
161	Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity. <i>Pulmonary Therapy</i> , 2023, 9, 71-89.	2.2	4
162	New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. <i>Annual Review of Medicine</i> , 2023, 74, 125-139.	12.2	20
163	Medications for the treatment of obesity. <i>Journal of Visceral Surgery</i> , 2023, 160, S12-S14.	0.8	1
164	Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?. <i>Cardiology in Review</i> , 2023, 31, 278-283.	1.4	2
165	Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?. <i>Cardiovascular Research</i> , 2024, 119, e167-e171.	3.8	5
166	The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 772.	2.4	4
167	Promising outcomes from latest landmark diabetes trials: tirzepatide and finerenone in the spotlight. <i>Practical Diabetes</i> , 2023, 40, 8-10.	0.3	0

#	ARTICLE	IF	CITATIONS
169	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. <i>Nutrients</i> , 2023, 15, 687.	4.1	12
170	Primary care physicians' perceptions of the effects of being overweight on all-cause mortality. <i>Epidemiology</i> , 0, Publish Ahead of Print, .	2.7	0
172	Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. <i>International Journal of Obesity</i> , 0, , .	3.4	1
173	Heart Disease and Stroke Statistics'2023 Update: A Report From the American Heart Association. <i>Circulation</i> , 2023, 147, .	1.6	2,130
174	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	7.3	358
175	Pharmacologic Treatment of Obesity in Reproductive Aged Women. <i>Current Obstetrics and Gynecology Reports</i> , 2023, 12, 138-146.	0.8	5
176	Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	7
177	Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin. <i>Clinical Diabetes</i> , 2023, 41, 367-377.	2.2	2
178	Current and emerging medications for the management of obesity in adults. <i>Medical Journal of Australia</i> , 2023, 218, 276-283.	1.7	5
179	Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials. <i>Aging Cell</i> , 2023, 22, .	6.7	1
180	Targeting G protein-coupled receptors to regulate energy homeostasis. <i>Journal of Molecular Endocrinology</i> , 2023, , .	2.5	0
183	Contemporary medical, device, and surgical therapies for obesity in adults. <i>Lancet</i> , The, 2023, 401, 1116-1130.	13.7	88
184	Variation in responses to incretin therapy: Modifiable and non-modifiable factors. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	1
185	Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review. <i>Adverse Drug Reaction Bulletin</i> , 2023, 339, 1315-1318.	0.5	1
186	Diagnosis and Management of Prediabetes. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1206.	7.4	59
187	Management of diabetes: Current concepts. <i>World Journal of Diabetes</i> , 0, 14, 396-411.	3.5	10
188	Research Priorities for Precision Medicine in NAFLD. <i>Clinics in Liver Disease</i> , 2023, 27, 535-551.	2.1	6
189	Novel therapeutics in rare genetic obesities: A narrative review. <i>Pharmacological Research</i> , 2023, 191, 106763.	7.1	2

#	ARTICLE	IF	CITATIONS
190	Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice. <i>Atherosclerosis</i> , 2023, 372, 19-31.	0.8	2
191	Current Treatment Options, Including Diet, Exercise, and Medications. <i>Clinics in Liver Disease</i> , 2023, 27, 397-412.	2.1	0
192	Obesity and Aging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 317-339.	3.2	9
193	Increased meal-induced neurotensin response predicts successful maintenance of weight loss “ Data from a randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2023, 143, 155534.	3.4	2
194	PYY (3-36) protects against high fat feeding induced changes of pancreatic islet and intestinal hormone content and morphometry. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2023, 1867, 130359.	2.4	1
195	Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?. <i>Cardiac Failure Review</i> , 0, 9, .	3.0	1
196	Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy. <i>Metabolism: Clinical and Experimental</i> , 2023, 142, 155531.	3.4	4
197	Integrating semaglutide into obesity management “ a primary care perspective. <i>Postgraduate Medicine</i> , 2022, 134, 37-49.	2.0	0
198	Efficacy and safety of semaglutide for weight management: evidence from the STEP program. <i>Postgraduate Medicine</i> , 2022, 134, 5-17.	2.0	12
199	Dual gut hormone receptor agonists for diabetes and obesity. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	7
200	A Call to Reconceptualize Obesity Treatment in Service of Health Equity: Review of Evidence and Future Directions. <i>Current Obesity Reports</i> , 2023, 12, 24-35.	8.4	5
201	Pharmacological Support for the Treatment of Obesity“Present and Future. <i>Healthcare (Switzerland)</i> , 2023, 11, 433.	2.0	6
202	Obesity-associated cancer risk reduction after metabolic surgery: insights from the SPLENDID study and the path forward. <i>Surgery for Obesity and Related Diseases</i> , 2023, 19, 788-793.	1.2	2
203	Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women. <i>Medical Clinics of North America</i> , 2023, 107, 285-298.	2.5	1
204	Obesity, metabolic and bariatric surgery, and cancer prevention: what do we need to learn and how do we get there?. <i>Surgery for Obesity and Related Diseases</i> , 2023, , .	1.2	2
205	Hormonal Gut“Brain Signaling for the Treatment of Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3384.	4.1	8
206	Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , 2023, 21, 27-47.	0.8	0
207	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 25-45.	3.6	14

#	ARTICLE	IF	CITATIONS
208	Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes. <i>Cardiovascular Endocrinology and Metabolism</i> , 2023, 12, e0279.	1.1	3
209	Future of bariatric surgery beyond simple weight loss: Metabolic surgery. <i>Journal of Visceral Surgery</i> , 2023, 160, S55-S62.	0.8	3
210	A "glucagon-like peptide-1 receptor agonist" dependent insulinotropic polypeptide therapy. <i>Orvosi Hetilap</i> , 2023, 164, 210-218.	0.4	0
211	Capturing the multifaceted function of adipose tissue macrophages. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
212	Levels of hormones regulating appetite and energy homeostasis in response to a 1.5-Year combined lifestyle intervention for obesity. <i>Frontiers in Physiology</i> , 0, 14, .	2.8	0
213	Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. <i>Nature Metabolism</i> , 2023, 5, 248-264.	11.9	24
214	Metabolically Healthy Obesity: Are Interventions Useful?. <i>Current Obesity Reports</i> , 2023, 12, 36-60.	8.4	4
215	Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. <i>Obesity</i> , 2023, 31, 1270-1279.	3.0	14
216	Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 407-418.	1.8	2
217	Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	2.7	1
218	A new kind of diabetes medication approved by the FDA: is there hope for obesity?. <i>International Journal of Surgery</i> , 2023, 109, 81-82.	2.7	1
219	Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 425-442.	329.8	6
220	Achieving Remission in the Era of Clinical Inertia: What Is Preventing Us from Treating Type 2 Diabetes?. <i>International Journal of Diabetology</i> , 2023, 4, 93-107.	2.0	0
221	The Case for Bariatric Surgery in Patients with Class 1 Obesity. <i>Current Surgery Reports</i> , 0, , .	0.9	0
222	How can physical activity facilitate a sustainable future? Reducing obesity and chronic disease. <i>Proceedings of the Nutrition Society</i> , 2023, 82, 286-297.	1.0	1
223	Precision Bariatric/Metabolic Medicine and Surgery. <i>Journal of Clinical Medicine</i> , 2023, 12, 1909.	2.4	0
224	Obesity and Kidney Transplantation—How to Evaluate, What to Do, and Outcomes. <i>Transplantation</i> , 0, Publish Ahead of Print, .	1.0	0
225	Current treatment landscape for obesity in Singapore. <i>Singapore Medical Journal</i> , 2023, 64, 172.	0.6	4

#	ARTICLE	IF	CITATIONS
226	Advent of tirzepatide: boon for diabetic and obese?. <i>Annals of Medicine and Surgery</i> , 2023, 85, 71-72.	1.1	1
227	Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review. <i>Clinical Therapeutics</i> , 2023, 45, 248-261.	2.5	2
228	Metabolically healthy obesity: Misleading phrase or healthy phenotype?. <i>European Journal of Internal Medicine</i> , 2023, 111, 5-20.	2.2	14
229	Pharmacological approaches to the prevention of type 2 diabetes mellitus. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	4
230	Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 693-711.	2.4	3
232	Obesity and the risk of cardiometabolic diseases. <i>Nature Reviews Cardiology</i> , 2023, 20, 475-494.	13.7	48
233	CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2023, 22, .	6.8	4
234	Comment on: Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery. <i>Surgery for Obesity and Related Diseases</i> , 2023, , .	1.2	0
235	The Fat Kidney. <i>Current Obesity Reports</i> , 0, , .	8.4	0
236	Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?. <i>Drugs</i> , 2023, 83, 469-477.	10.9	1
237	Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. <i>EClinicalMedicine</i> , 2023, 58, 101882.	7.1	65
238	Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention. <i>Healthcare (Switzerland)</i> , 2023, 11, 902.	2.0	15
239	Ten reasons gastroenterologists and hepatologists should be treating obesity. <i>Gut</i> , 2023, 72, 1033-1038.	12.1	6
240	Long-term Outcomes Following Adolescent Metabolic and Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2184-2192.	3.6	4
241	Molecular Pathology and Therapeutic Strategies of Type 2 Diabetes. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, .	1.2	0
242	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2023, 396, 1619-1632.	3.0	2
243	Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective. <i>Obesity Reviews</i> , 2023, 24, .	6.5	2
244	Novel Anti-Obesity Pharmacotherapies. , 0, , .		0

#	ARTICLE	IF	CITATIONS
245	Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, , .	2.6	3
246	A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	3
247	Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6192.	4.1	19
249	The need to personalise approaches for the prevention and management of obesity. <i>EClinicalMedicine</i> , 2023, 58, 101944.	7.1	0
250	Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). <i>Swiss Medical Weekly</i> , 2023, 153, 40060.	1.6	5
251	Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3. <i>Diabetes Therapy</i> , 0, , .	2.5	0
252	Global Impact of Obesity. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 277-293.	2.2	6
253	The Physiological Regulation of Body Fat Mass. <i>Gastroenterology Clinics of North America</i> , 2023, , .	2.2	0
254	Tirzepatide decreases systolic and diastolic blood pressure. <i>European Journal of Internal Medicine</i> , 2023, 114, 135-137.	2.2	3
256	New insights into the treatment of obesity. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2058-2072.	4.4	21
257	A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. <i>Life</i> , 2023, 13, 1012.	2.4	4
258	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. <i>Life</i> , 2023, 13, 1024.	2.4	1
259	Tirzepatide: Clinical review of the "twincretin" injectable. <i>American Journal of Health-System Pharmacy</i> , 2023, 80, 879-888.	1.0	2
260	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1835-1878.	2.8	74
261	Gene Therapy Based on Mesenchymal Stem Cells Derived from Adipose Tissue for the Treatment of Obesity and Its Metabolic Complications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7468.	4.1	5
262	Liver Transplantation 2023: Status Report, Current and Future Challenges. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2150-2166.	4.4	14
263	Distinct Roles for Brain and Pancreas in Basal and Postprandial Glucose Homeostasis. <i>Diabetes</i> , 2023, 72, 547-556.	0.6	3
264	Designer GLP1 poly-agonist peptides in the management of diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 231-240.	2.4	1

#	ARTICLE	IF	CITATIONS
265	Bariatric“metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. <i>Lancet</i> , The, 2023, 401, 1786-1797.	13.7	48
266	Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	47
267	Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 355-359.	4.1	6
268	A Women's health perspective on managing obesity. <i>Progress in Cardiovascular Diseases</i> , 2023, 78, 11-16.	3.1	3
269	Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2023, 29, 564-568.	0.9	0
270	Sleep Apnea, Obesity, and Diabetes “an Intertwined Trio. <i>Current Diabetes Reports</i> , 2023, 23, 165-171.	4.2	2
271	A Survey of Obesity Education and Training in United States Pharmacy Schools. <i>American Journal of Pharmaceutical Education</i> , 2023, 87, 100109.	2.1	0
272	Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. <i>Nature Reviews Cardiology</i> , 2023, 20, 685-695.	13.7	14
273	Weight loss with subcutaneous semaglutide versus other glucagon“like peptide 1 receptor agonists in type 2 diabetes: a systematic review. <i>Internal Medicine Journal</i> , 2023, 53, 1311-1320.	0.8	2
274	Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2023, 2023, 1-8.	2.3	6
275	Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease“Current Background, Hopes, and Perspectives. <i>Metabolites</i> , 2023, 13, 581.	2.9	2
276	General Treatment of Pediatric Obesity. , 2023, , 251-286.		0
277	Determinants of excessive weight gain after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 60). <i>Diabetes Research and Clinical Practice</i> , 2023, 200, 110719.	2.8	2
278	Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications. <i>Current Obesity Reports</i> , 2023, 12, 127-146.	8.4	5
279	Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. <i>Diabetologia</i> , 2023, 66, 1796-1808.	6.3	20
280	A review of the evidence on cardiovascular outcomes from obesity treatment. , 2023, 7, 100071.		3
281	Clinical evaluation of patients living with obesity. <i>Internal and Emergency Medicine</i> , 0, , .	2.0	2
282	Editorial: “being normal weight each day keeps NAFLD and fibrosis away“the importance of reducing cumulative exposure to overweight. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1168-1169.	3.7	0

#	ARTICLE	IF	CITATIONS
283	Dysglycemia Shapes Visceral Adipose Tissue's Response to GIP, GLP-1 and Glucagon in Individuals with Obesity. <i>Metabolites</i> , 2023, 13, 587.	2.9	0
285	Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities. <i>Journal of the National Cancer Institute Monographs</i> , 2023, 2023, 68-76.	2.1	0
286	American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. <i>Endocrine Practice</i> , 2023, 29, 305-340.	2.1	46
287	The Neurobiology of Eating Behavior in Obesity: Mechanisms and Therapeutic Targets: A Report from the 23rd Annual Harvard Nutrition Obesity Symposium. <i>American Journal of Clinical Nutrition</i> , 2023, 118, 314-328.	4.7	2
288	Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2023, 148, 74-94.	1.6	11
290	Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 659-669.	5.0	0
291	Cardiorenal syndrome and diabetes: an evil pairing. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
293	Tirzepatide and potential use for metabolically healthy obesity. <i>European Journal of Internal Medicine</i> , 2023, 113, 1-5.	2.2	6
294	Mechanisms underlying the efficacy of a rodent model of vertical sleeve gastrectomy – A focus on energy expenditure. <i>Molecular Metabolism</i> , 2023, 73, 101739.	6.5	1
295	Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. <i>European Journal of Heart Failure</i> , 2023, 25, 936-955.	7.1	20
296	Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. <i>JACC: Heart Failure</i> , 2023, 11, 1000-1010.	4.1	16
297	CKD therapy to improve outcomes of immune-mediated glomerular diseases. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, ii50-ii57.	0.7	4
298	Game-changing obesity drugs go mainstream: what scientists are learning. <i>Nature</i> , 2023, 618, 17-18.	27.8	2
300	Obesity-related hypertension. <i>Nurse Practitioner</i> , 2023, 48, 8-15.	0.3	0
301	Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9324.	4.1	4
302	Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2561-2574.	4.4	3
303	G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children. <i>Biomedicines</i> , 2023, 11, 1576.	3.2	0
304	Pharmacotherapy for chronic obesity management: a look into the future. <i>Internal and Emergency Medicine</i> , 0, , .	2.0	0



#	ARTICLE	IF	CITATIONS
305	Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 0, , .	4.4	1
306	Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. <i>International Journal of Obesity</i> , 2023, 47, 677-685.	3.4	10
307	Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials. , 2023, 14, 65-73.		1
308	Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. <i>Diabetes Care</i> , 2023, 46, 1501-1506.	8.6	5
309	Obesity: medical management. <i>Medicine</i> , 2023, 51, 509-514.	0.4	0
310	Perspectives on weight control in diabetes – Tirzepatide. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110770.	2.8	4
311	The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. <i>Nature Metabolism</i> , 2023, 5, 945-954.	11.9	18
312	Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	6
313	Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. <i>Canadian Journal of Anaesthesia</i> , 2023, 70, 1397-1400.	1.6	22
314	The sun is rising on a new era of pharmacotherapy for obesity: some words of caution. <i>Surgery for Obesity and Related Diseases</i> , 2023, , .	1.2	0
315	Bariatric surgery the best potential treatment for nonalcoholic fatty liver disease (NAFLD). <i>International Journal of Surgery Global Health</i> , 2023, 6, .	0.3	0
317	A phenotypic approach to obesity treatment. <i>Nutrition in Clinical Practice</i> , 2023, 38, 959-975.	2.4	0
318	Philosophically, is obesity really a disease?. <i>Obesity Reviews</i> , 0, , .	6.5	2
319	Psychological and medical treatments for binge-eating disorder: A research update. <i>Physiology and Behavior</i> , 2023, 269, 114267.	2.1	2
321	360-Degree Perspectives on Obesity. <i>Medicina (Lithuania)</i> , 2023, 59, 1119.	2.0	5
322	A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
323	Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. , 2023, 7, 100076.		3
324	A diabetes update. <i>Journal of Diabetes</i> , 0, , .	1.8	0

#	ARTICLE	IF	CITATIONS
325	Reply to "New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy". Obesity Surgery, 0, , .	2.1	0
326	Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue <sc>HM15136</sc> in overweight and obese patients with co-morbidities. Diabetes, Obesity and Metabolism, 2023, 25, 2723-2733.	4.4	0
327	Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 1767-1774.	2.4	2
328	Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease. Ageing Research Reviews, 2023, 89, 101979.	10.9	9
329	The prospective record-breaking obesity drug tirzepatide raises concerns about affordability. Journal of Basic and Clinical Physiology and Pharmacology, 2023, .	1.3	1
331	Subclinical Reactive Hypoglycemia with Low Glucose Effectiveness "Why We Cannot Stop Snacking despite Gaining Weight. Metabolites, 2023, 13, 754.	2.9	2
332	Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss. European Journal of Pharmacology, 2023, 954, 175837.	3.5	2
333	Current and future pharmacotherapies for obesity in children and adolescents. Nature Reviews Endocrinology, 2023, 19, 534-541.	9.6	4
334	Partial Meal Replacement for Weight Loss after Stroke: Results of a Pilot Clinical Trial. Cerebrovascular Diseases, 2024, 53, 54-61.	1.7	1
336	Induction of remission in diabetes by lowering blood glucose. Frontiers in Endocrinology, 0, 14, .	3.5	1
337	Liver disease is a significant risk factor for cardiovascular outcomes " A UK Biobank study. Journal of Hepatology, 2023, 79, 1085-1095.	3.7	11
338	New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy. Obesity Surgery, 0, , .	2.1	1
339	<sc>GLP-1</sc> agonists for people living with <sc>HIV</sc> and obesity, is there a potential?. HIV Medicine, 2023, 24, 1029-1034.	2.2	3
341	Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences, 2023, 24, 10449.	4.1	11
342	News in diabetology 2022. Vnitri Lekarstvi, 2023, 69, 270-273.	0.2	0
344	Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 2023, 389, 877-888.	27.0	61
345	Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. Journal of Obesity and Metabolic Syndrome, 2023, 32, 106-120.	3.6	6
346	2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. Journal of Hypertension, 2023, 41, 1874-2071.	0.5	267

#	ARTICLE	IF	CITATIONS
348	CagriSema and the link between obesity and type 2 diabetes. <i>Lancet, The</i> , 2023, 402, 671-673.	13.7	1
349	Obesity and diabetes. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110773.	2.8	10
350	Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death. , 2023, 7, 100077.		0
351	Obesity and atrial fibrillation: Prevalence, pathogenesis, and prognosis. <i>Progress in Cardiovascular Diseases</i> , 2023, 78, 34-42.	3.1	7
352	Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 989-1000.	1.8	3
353	Current pharmacological approaches in obesity treatment. , 2023, 3, 32-48.		0
354	Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 307-319.	2.4	5
355	Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. <i>Cureus</i> , 2023, , .	0.5	4
356	Maternal Weight Management to Prevent the Developmental Programming of MAFLD in Offspring of Obese Mothers. <i>Nutrients</i> , 2023, 15, 2155.	4.1	2
357	GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. <i>Cell Reports</i> , 2023, 42, 112466.	6.4	1
358	Genetically proxied impaired GIPR signaling and risk of 6 cancers. <i>IScience</i> , 2023, 26, 106848.	4.1	0
359	Cancer cachexia as a blueprint for treating obesity. <i>Trends in Endocrinology and Metabolism</i> , 2023, 34, 395-403.	7.1	1
360	Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8592.	4.1	2
362	Obesity wars: hypothalamic sEVs a new hope. <i>Trends in Molecular Medicine</i> , 2023, 29, 622-634.	6.7	3
363	Child and adolescent obesity. <i>Nature Reviews Disease Primers</i> , 2023, 9, .	30.5	39
364	Will Tirzepatide Become a Game-Changer Anti-Obesity Drug?. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 532-533.	0.9	0
365	Health care providers' attitudes and counseling behaviors related to obesity. <i>Obesity Science and Practice</i> , 0, , .	1.9	0
366	Body weight time in target range and cardiovascular outcomes in adults with overweight/obesity and type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	1

#	ARTICLE	IF	CITATIONS
367	Obesity management for cardiovascular disease prevention. , 2023, 7, 100069.		3
368	Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase. <i>Primary Care Diabetes</i> , 2023, 17, 366-372.	1.8	2
369	Engineering bacteria to modulate host metabolism. <i>Acta Physiologica</i> , 2023, 238, .	3.8	0
370	Heart Failure and Obesity: The Latest Pandemic. <i>Progress in Cardiovascular Diseases</i> , 2023, 78, 43-48.	3.1	7
371	Circadian control of white and brown adipose tissues. <i>Current Opinion in Genetics and Development</i> , 2023, 80, 102056.	3.3	1
372	Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist. <i>Journal of the American Chemical Society</i> , 2023, 145, 12105-12114.	13.7	1
373	A systematic review of the economic value proposition for commercially available <scp>nonsurgical</scp> weight loss interventions. <i>Obesity</i> , 2023, 31, 1725-1733.	3.0	2
374	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2022. <i>American Journal of Medicine</i> , 2023, , .	1.5	0
376	Gut hormone co-agonists for the treatment of obesity: from bench to bedside. <i>Nature Metabolism</i> , 2023, 5, 933-944.	11.9	15
377	SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide. <i>Lancet, The</i> , 2023, , .	13.7	0
378	Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2023, 402, 613-626.	13.7	73
379	A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena. <i>Lancet, The</i> , 2023, , .	13.7	0
380	Tripleâ€‘Hormone-Receptor Agonist Retatrutide for Obesity â€‘ A Phase 2 Trial. <i>New England Journal of Medicine</i> , 2023, 389, 514-526.	27.0	143
381	Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 2213-2236.	3.3	2
382	Shorter History of Hypertension as a Predictor of Hypertension Remission after 3-years of Bariatric Surgery: Data from the GATEWAY Trial. <i>Obesity Surgery</i> , 2023, 33, 2485-2492.	2.1	0
383	Effect of bariatric surgery on cardio-psycho-metabolic outcomes in severe obesity: A randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2023, 147, 155655.	3.4	3
384	Ketogenic diets for obesityâ€‘hypoventilation syndrome? Interesting physiology but a long way to go. <i>Respirology</i> , 2023, 28, 701-702.	2.3	1
385	Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review. <i>Biomedicines</i> , 2023, 11, 1875.	3.2	0

#	ARTICLE	IF	CITATIONS
387	Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 921-936.	5.7	2
388	GPCR-mediated effects of fatty acids and bile acids on glucose homeostasis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	3
389	Impact of nutritional, behavioral and supervised exercise intervention following bariatric surgery: The <sc>BARI-LIFESTYLE</sc> randomized controlled trial. <i>Obesity</i> , 2023, 31, 2031-2042.	3.0	4
390	Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. <i>Canadian Journal of Cardiology</i> , 2023, 39, 1816-1838.	1.7	2
391	The potential impact of <sc>GLP</sc> agonists on obstructive sleep apnoea. <i>Respirology</i> , 2023, 28, 824-825.	2.3	2
392	The Management of Obesity in 2023: An Update. , 0, , .		0
393	The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome. <i>Journal of Clinical Medicine</i> , 2023, 12, 4575.	2.4	0
394	Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug. <i>Klinicka Farmakologie A Farmacie</i> , 2023, 37, 68-71.	0.2	0
395	Weight gain after HIV therapy initiation: pathophysiology and implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	3
396	Go Big or Go Home: Obesity and Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2023, 38, 1928-1937.	3.1	2
398	Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity. <i>American Journal of Therapeutics</i> , 2023, 30, e347-e352.	0.9	3
399	Effect of the Dual Glucose-Dependent Insulinotropic Peptide/Glucagon-Like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2023, 45, 787-796.	2.5	3
400	Updates in the Treatment of Pediatric Obesity. <i>Current Treatment Options in Pediatrics</i> , 2023, 9, 93-105.	0.6	1
401	Behaviour change in the era of biomedical advances. <i>Nature Human Behaviour</i> , 0, , .	12.0	2
402	Ordinaries 12. <i>Journal of Bioeconomics</i> , 2023, 25, 75-98.	3.3	2
403	Obesity represents a persisting health issue in axial spondyloarthritis, particularly affecting socially disadvantaged patients. <i>Journal of Rheumatology</i> , 0, , jrheum.2023-0137.	2.0	2
404	Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice. <i>European Journal of Pharmacology</i> , 2023, 955, 175912.	3.5	1
405	Are GLP-1R agonists the long-sought-after panacea for obesity?. <i>Trends in Molecular Medicine</i> , 2023, , .	6.7	0

#	ARTICLE	IF	CITATIONS
406	Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of SEMI (Spanish Society of Internal Medicine). <i>Revista Espanola de Medicina Interna</i> , 2023, 223, 493-498.	0.5	0
407	Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. <i>International Journal of Obesity</i> , 2023, 47, 883-892.	3.4	8
408	Obesity in Heart Failure with Reduced Ejection Fraction. <i>Cardiology Clinics</i> , 2023, , .	2.2	0
409	Management of abdominal wall hernias in patients with severe obesity. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 6619-6626.	2.4	3
410	Breaking down silos: the multifaceted nature of obesity and the future of weight management. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2023, 378, .	4.0	2
411	Blockbuster Medications for Obesity: A Primer for Nephrologists. <i>American Journal of Kidney Diseases</i> , 2023, 82, 762-771.	1.9	0
412	Should Prediabetes be Treated Pharmacologically?. <i>Diabetes Therapy</i> , 2023, 14, 1585-1593.	2.5	1
413	Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery. <i>JAMA Surgery</i> , 2023, 158, 1003.	4.3	18
414	The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review. <i>Aesthetic Surgery Journal</i> , 2023, 44, 68-79.	1.6	2
415	Targets for obstructive sleep apnea pharmacotherapy: principles, approaches, and emerging strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2023, 27, 609-626.	3.4	1
416	Small intestine is a big player!. <i>Digestive Endoscopy</i> , 2023, 35, 698-699.	2.3	0
417	The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2023, 66, 1846-1858.	6.3	6
418	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2023, 82, 833-955.	2.8	48
420	Incretin Analogs for Weight Management in Adults Without Diabetes. <i>Annals of Pharmacotherapy</i> , 0, , .	1.9	0
421	Management of hyperglycaemia in people with obesity. <i>Clinical Medicine</i> , 2023, 23, 364-371.	1.9	1
422	Medical Weight Optimization for Arthroplasty Patients: A Primer of Emerging Therapies for the Joint Arthroplasty Surgeon. <i>Journal of Arthroplasty</i> , 2024, 39, 38-43.	3.1	1
423	Future therapies for obesity. <i>Clinical Medicine</i> , 2023, 23, 337-346.	1.9	4
424	Cardiovascular risk stratification among individuals with obesity: The Coronary Artery Calcium Consortium. <i>Obesity</i> , 2023, 31, 2240-2248.	3.0	1

#	ARTICLE	IF	CITATIONS
425	Response to: Low-calorie Diets for Remission of Type 2 Diabetes--Do the Benefits Outweigh the Risks?. Canadian Journal of Diabetes, 2023, , .	0.8	0
426	Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023. , 2023, 8, 100083.		4
427	The importance of glucoseâ€dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes, Obesity and Metabolism, 2023, 25, 3079-3092.	4.4	5
428	Review of Prediabetes. JAMA - Journal of the American Medical Association, 2023, 330, 564.	7.4	0
429	The energy-rush and insulin model of obesity. Research Ideas and Outcomes, 0, 9, .	1.0	0
430	The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and metaâ€regression analysis of randomized controlled trials. Frontiers in Endocrinology, 0, 14, .	3.5	2
431	Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. Journal of Hepatology, 2023, 79, 1557-1565.	3.7	8
432	Cellular mechanism of diabetes remission by bariatric surgery. Trends in Endocrinology and Metabolism, 2023, 34, 590-600.	7.1	1
433	US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events. Cardiovascular Drugs and Therapy, 0, , .	2.6	2
434	Development of a novel <sc>Fc</sc> fusion protein dual glucagonâ€like peptideâ€1 and gastric inhibitory polypeptide receptor agonists. Diabetes, Obesity and Metabolism, 2023, 25, 3356-3365.	4.4	1
435	The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide. Diabetes Research and Clinical Practice, 2023, 203, 110881.	2.8	1
436	Is Metabolic Surgery Having an Identity Crisis?. Obesity Surgery, 0, , .	2.1	0
437	Endoscopic Sleeve Gastroplasty in Those with a BMI of 27-30. American Journal of Gastroenterology, 2023, , .	0.4	1
438	GIPR/GLP-1R dual agonist therapies for diabetes and weight lossâ€chemistry, physiology, and clinical applications. Cell Metabolism, 2023, 35, 1519-1529.	16.2	18
439	Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report. Journal of the American Pharmacists Association: JAPhA, 2023, 63, 1821-1825.	1.5	1
440	NK cells vs. obesity: A tale of dysfunction & redemption. Clinical Immunology, 2023, 255, 109744.	3.2	0
441	A narrative review of approved and emerging anti-obesity medications. Saudi Pharmaceutical Journal, 2023, 31, 101757.	2.7	4
442	2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal, 2023, 44, 4043-4140.	2.2	88

#	ARTICLE	IF	CITATIONS
444	Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. <i>Diabetes Care</i> , 2023, 46, 1574-1586.	8.6	16
445	Effects of Replacing a Central Glycine Residue in GLP-1 on Receptor Affinity and Signaling Profile. <i>ChemBioChem</i> , 0, , .	2.6	0
446	Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	3
447	The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions. <i>Neurogastroenterology and Motility</i> , 2024, 36, .	3.0	3
448	Dietary Vitamin A Affects the Function of Incretin-Producing Enteroendocrine Cells in Male Mice Fed a High-Fat Diet. <i>Journal of Nutrition</i> , 2023, 153, 2901-2914.	2.9	0
449	Protective Factors and the Pathogenesis of Complications in Diabetes. <i>Endocrine Reviews</i> , 2024, 45, 227-252.	20.1	4
450	The protective role of GLP-1 in neuro-ophthalmology. , 0, , 221-238.		0
451	Down the Rabbit Hole: Reviewing the Evidence for Primary Prevention of Cardiovascular Disease in People with Obesity. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	0
452	HIV Treatment and Obesity: What's New?. <i>Infectious Diseases</i> , 0, , .	4.0	0
453	Pharmacotherapy for obstructive sleep apnea: targeting specific pathophysiological traits. <i>Expert Review of Respiratory Medicine</i> , 2023, 17, 663-673.	2.5	3
454	Lifestyle Modification for the Management of Psoriatic Arthritis. <i>American Journal of Lifestyle Medicine</i> , 0, , .	1.9	0
455	Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus. <i>International Journal of Diabetes in Developing Countries</i> , 2024, 44, 200-209.	0.8	0
456	GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice. <i>Peptides</i> , 2023, , 171093.	2.4	0
457	Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 4934-4947.	5.4	0
458	Endoluminal bariatric and metabolic therapies: state-of-the-art. <i>Current Opinion in Gastroenterology</i> , 2023, 39, 362-369.	2.3	0
459	Obesity-induced and weight-loss-induced physiological factors affecting weight regain. <i>Nature Reviews Endocrinology</i> , 2023, 19, 655-670.	9.6	4
460	Differential mechanisms affecting weight loss and weight loss maintenance. <i>Nature Metabolism</i> , 2023, 5, 1266-1274.	11.9	4
461	Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management. <i>Advances in Medicine</i> , 2023, 2023, 1-7.	0.8	3



#	ARTICLE	IF	CITATIONS
462	Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?. <i>Future Cardiology</i> , 2023, 19, 301-312.	1.2	0
463	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2023, 148, .	1.6	84
464	Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. <i>Biomedicines</i> , 2023, 11, 2498.	3.2	3
465	Diabetocardiology: a new subspecialty?. <i>European Heart Journal</i> , 2023, 44, 4214-4216.	2.2	3
466	Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review. <i>JBMR Plus</i> , 2023, 7, .	2.7	0
467	Association of Eating Behaviors with Variability in Weight Change in Response to Physical Activity Interventions in Adults with Overweight. <i>Nutrients</i> , 2023, 15, 3452.	4.1	0
468	Metabolic and Bariatric Endoscopy: A Mini-Review. <i>Life</i> , 2023, 13, 1905.	2.4	1
469	Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs. <i>Cureus</i> , 2023, , .	0.5	0
470	Obesity drug shortages are symptomatic of wider malaise. <i>Lancet, The</i> , 2023, , .	13.7	2
471	Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes. <i>Diabetes Therapy</i> , 2023, 14, 1771-1784.	2.5	1
472	Synergistic combinations of gut-and-pancreas hormone-based therapies: Advancements in treatments for metabolic diseases. <i>Endocrinology</i> , 0, , .	2.8	0
473	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. <i>Nature Medicine</i> , 2023, 29, 2909-2918.	30.7	26
474	Our biology working against us in obesity: A narrative review on implications for management of osteoarthritis. <i>Osteoarthritis and Cartilage Open</i> , 2023, 5, 100407.	2.0	2
475	Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis. <i>EMBO Molecular Medicine</i> , 2023, 15, .	6.9	1
476	A revolution in obesity treatment. <i>Nature Medicine</i> , 2023, 29, 2406-2408.	30.7	6
477	Association of metabolic syndrome and chronic kidney disease. <i>Obesity Reviews</i> , 2024, 25, .	6.5	2
478	Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. <i>Cardiovascular Diabetology</i> , 2023, 22, .	6.8	2
479	Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?. , 2023, 251, 108549.		3

#	ARTICLE	IF	CITATIONS
480	Beyond glycemia: Comparing tirzepatide to GLP-1 analogues. <i>Reviews in Endocrine and Metabolic Disorders</i> , 0, , .	5.7	1
481	Association between weight reduction and employeesâ€™™ healthcare cost. <i>Journal of Occupational and Environmental Medicine</i> , 0, , .	1.7	0
482	Body Mass Index, Obesity, and Mortalityâ€™™Part II. <i>Nutrition Today</i> , 2023, 58, 158-164.	1.0	1
483	Four key questions on the new wave of anti-obesity drugs. <i>Nature</i> , 2023, 620, 28-30.	27.8	1
484	Diagnosis and treatment of prediabetes as prevention of type 2 diabetes: A review. <i>Consilium Medicum</i> , 2023, 25, 229-235.	0.3	0
485	Obesidad : Un breve repaso a su tratamiento. <i>Revista De La Facultad De Medicina</i> , 2023, 1, 80-84.	0.0	0
489	Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?. <i>Sleep</i> , 2023, 46, .	1.1	2
490	Next Chapter for Weight Control â€™™ Small-Molecule GLP-1 Receptor Agonists?. <i>New England Journal of Medicine</i> , 2023, 389, 949-950.	27.0	2
491	Promoting metabolic inefficiency for metabolic disease. <i>IScience</i> , 2023, 26, 107843.	4.1	1
493	Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. <i>Molecular Metabolism</i> , 2023, 78, 101801.	6.5	7
494	The â€™™Behavioral Balance Modelâ€™™™: A new perspective on the aetiology and therapy of obesity. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3444-3452.	4.4	1
495	Pharmacotherapy of Obesity: An Updated Overview. <i>Journal for Nurse Practitioners</i> , 2023, 19, 104750.	0.8	0
496	The liver adventures of bariatric endoscopy. <i>Endoscopy</i> , 0, , .	1.8	0
497	Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. <i>EClinicalMedicine</i> , 2023, 64, 102181.	7.1	7
498	Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	2
499	Effect of tirzepatide on blood pressure and lipids: A metaâ€™™analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3766-3778.	4.4	7
500	Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the <sc>SURMOUNT</sc>â€™™1 trial. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3748-3756.	4.4	2
501	Identifying obesity subtypes: A review of studies utilising clinical biomarkers and genetic data. <i>Diabetic Medicine</i> , 2023, 40, .	2.3	2

#	ARTICLE	IF	CITATIONS
502	Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 719-742.	4.7	1
504	Preoperative Patient Evaluation. <i>Anesthesiology Clinics</i> , 2023, , .	1.4	0
505	Acupuncture as multi-targeted therapy for the multifactorial disease obesity: a complex neuro-endocrine-immune interplay. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
506	Obesity management for the hepatologist â€“ what to do, how to do it and why. <i>Hepatology</i> , 0, , .	7.3	0
507	Strategies for Long-Term Weight Loss and Maintenance. <i>Korean Journal of Family Practice</i> , 2023, 13, 128-137.	0.3	0
508	Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2023, 325, E595-E609.	3.5	1
509	The Effective Use of Anti-obesity Medications. <i>Gastroenterology Clinics of North America</i> , 2023, , .	2.2	0
510	The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. <i>Journal of Lipid and Atherosclerosis</i> , 2023, 12, 213.	3.5	2
511	Adipose Tissue and Metabolic Health. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 595-611.	4.7	1
512	Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	2
514	Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2023, , .	0.4	0
515	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
516	Obesity, Metabolic Syndrome, and Sleep Disorders. , 2023, , 1-20.		0
517	Gut Hormones and Metabolic Syndrome. , 2023, , 1-16.		0
518	Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2023, , .	4.1	1
519	Approach the Patient With Obstructive Sleep Apnea and Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2024, 109, e1267-e1279.	3.6	1
522	Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. <i>Cureus</i> , 2023, , .	0.5	0
523	Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1Âmg in Patients with Type 2 Diabetes in the United States. <i>Diabetes Therapy</i> , 2023, 14, 2045-2055.	2.5	0

#	ARTICLE	IF	CITATIONS
524	Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 0, , .	2.2	0
525	Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years. <i>Presse Medicale</i> , 2023, 52, 104178.	1.9	0
526	Management of Medication-Induced Weight Gain. <i>Gastroenterology Clinics of North America</i> , 2023, , .	2.2	0
527	Precision medicine of obesity as an integral part of type 2 diabetes management â€“ past, present, and future. <i>Lancet Diabetes and Endocrinology</i> , the, 2023, 11, 861-878.	11.4	5
528	Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. <i>Current Opinion in Cardiology</i> , 2023, 38, 539-545.	1.8	1
529	Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2024, 64, 169-173.	1.5	1
530	Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline <scp>glycated haemoglobin level</scp> in Japanese patients with type 2 diabetes: A subgroup analysis of the <scp>SURPASS</scp> Jâ€™mono study. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 126-134.	4.4	0
531	Diabesity Treatments Today and Tomorrow. <i>ADCES in Practice</i> , 2023, 11, 26-32.	0.2	0
532	Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. <i>Diabetologia</i> , 0, , .	6.3	0
533	A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2023, 148, 1636-1664.	1.6	14
534	Characteristics of the Latest Therapeutic Agent for Diabetes. <i>Journal of Korean Diabetes</i> , 2023, 24, 148-153.	0.3	0
535	Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2024, 64, 133-138.	1.5	1
537	Treating obesity in type 1 diabetes mellitus â€“ review of efficacy and safety. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2024, 31, 1-7.	2.3	1
538	Proportion of caloric restrictionâ€™induced weight loss as skeletal muscle. <i>Obesity</i> , 2024, 32, 32-40.	3.0	0
539	Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin. <i>Diabetes Therapy</i> , 2023, 14, 1997-2014.	2.5	1
541	Anti-obesity drugsâ€™ side effects: what we know so far. <i>Nature</i> , 2023, 622, 682-682.	27.8	0
542	Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery. <i>Biomedicines</i> , 2023, 11, 2785.	3.2	1
543	Recent Updates on Pharmacologic Therapy in Nonalcoholic Fatty Liver Disease. <i>Clinical and Molecular Hepatology</i> , 0, , .	8.9	0

#	ARTICLE	IF	CITATIONS
544	Microvascular Dysfunction in Obesity-Hypertension. <i>Current Hypertension Reports</i> , 2023, 25, 447-453.	3.5	1
545	The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, , 189000.	7.4	0
546	Severe hypertriglyceridemia: Existing and emerging therapies. , 2023, 251, 108544.		3
547	Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
548	High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	2
549	Novel <i>cannabinoid receptor 1</i> inverse agonist <i>CRB</i> 13 enhances efficacy of tirzepatide, semaglutide, and liraglutide in the diet-induced obesity mouse model. <i>Obesity</i> , 2023, 31, 2676-2688.	3.0	0
550	Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and expanding <i>A. muciniphila</i> . <i>Cell Reports Medicine</i> , 2023, 4, 101235.	6.5	0
553	A literature review of evidence for primary prevention of overweight and obesity in healthy weight children and adolescents: A report produced by a working group of the Danish Council on Health and Disease Prevention. <i>Obesity Reviews</i> , 2024, 25, .	6.5	1
554	Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 0, , .	2.9	0
555	Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy improves lipid and glucose homeostasis in ob/ob mice. <i>Obesity</i> , 2024, 32, 91-106.	3.0	0
556	Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes. <i>Diabetes</i> , 0, , .	0.6	0
557	Pharmacological Strategies for Pediatric Obesity. , 2023, , 139-210.		0
558	Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller. , 0, , .		0
559	Management of Type 2 Diabetes Mellitus. , 0, , .		0
560	Medikamente zur Behandlung von Essstörungen und Adipositas. , 2023, , 803-829.		0
561	The pathogenesis of obesity in people living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2024, 19, 6-13.	3.8	0
562	Retatrutide: a triple incretin receptor agonist for obesity management. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 1003-1008.	4.1	0
563	Relevance and consequence of chronic inflammation for obesity development. <i>Molecular and Cellular Pediatrics</i> , 2023, 10, .	1.8	0

#	ARTICLE	IF	CITATIONS
564	Navigating the Role of Anti-Obesity Agents Prior to Pregnancy: A Narrative Review. <i>Seminars in Reproductive Medicine</i> , 0, , .	1.1	0
565	From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention. <i>Cancers</i> , 2023, 15, 5458.	3.7	0
566	Enteroendocrine cell regulation of the gut-brain axis. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	4
567	Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based coagonists. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
568	Anti-obesity pharmacotherapy in adults with chronic kidney disease. <i>Kidney International</i> , 2023, , .	5.2	1
569	Is obesity the next step in evolution through brain changes?. , 2024, 3, 103927.		0
570	Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
571	Structure, function and drug discovery of GPCR signaling. <i>Molecular Biomedicine</i> , 2023, 4, .	4.4	4
572	Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction. <i>Circulation: Heart Failure</i> , 2023, 16, .	3.9	0
573	Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size. , 2023, 8, 100094.		0
574	Game changers: do new medications make lifestyle-based treatment of obesity obsolete?. <i>Obesity</i> , 2024, 32, 237-239.	3.0	1
575	Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm. <i>Gut</i> , 0, , gutjnl-2023-330771.	12.1	2
576	TO MARKET, TO MARKET—2022: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 713-798.	0.1	0
577	Ordinaries 13: apparent spite & apparent altruism. <i>Journal of Bioeconomics</i> , 0, , .	3.3	0
578	A closer look at weight loss interventions in primary care: a systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
579	The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. <i>Current Obesity Reports</i> , 2023, 12, 453-473.	8.4	5
580	GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108647.	2.3	1
581	[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. <i>Actas Dermo-sifiliográficas</i> , 2023, , .	0.4	0

#	ARTICLE	IF	CITATIONS
582	Newer pharmacological interventions directed at gut hormones for obesity. <i>British Journal of Pharmacology</i> , 0, , .	5.4	0
584	Intersections between HIV and obesity in emerging economies. <i>Current Opinion in HIV and AIDS</i> , 2024, 19, 35-44.	3.8	0
585	Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review. <i>Metabolism: Clinical and Experimental</i> , 2024, 151, 155721.	3.4	0
586	Inflammation Is a Histological Characteristic of Skeletal Muscle in Chronic Limb Threatening Ischemia. <i>Annals of Vascular Surgery</i> , 2024, 99, 10-18.	0.9	0
588	GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice. <i>Diabetes</i> , 2024, 73, 292-305.	0.6	0
589	Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 319-328.	4.4	3
590	Effects of <i>CB1R</i> inverse agonist, <i>INV-020</i> , in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 642-649.	4.4	0
591	Retatrutide showing promise in obesity (and type 2 diabetes). <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 997-1001.	4.1	0
592	Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting. <i>American Journal of the Medical Sciences</i> , 2024, 367, 77-88.	1.1	1
593	Impact of a Food Rebalancing Program Associated with Plant-Derived Food Supplements on the Biometric, Behavioral, and Biological Parameters of Obese Subjects. <i>Nutrients</i> , 2023, 15, 4780.	4.1	0
594	Tirzepatide maintained significant weight loss when treatment was continued in a follow-up study. <i>Diabetes Obesity and Metabolism Now</i> , 2023, 1, .	0.0	0
595	The cardiovascular effects of novel weight loss therapies. <i>European Heart Journal</i> , 2023, 44, 5036-5048.	2.2	5
596	Weight regain after endoscopic sleeve gastroplasty: retightening the sutures, starting a pill, and more. <i>Gastrointestinal Endoscopy</i> , 2023, 98, 950-952.	1.0	0
597	Beyond pounds: What else could be lost?. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108649.	2.3	0
598	Effects of Diet Macronutrient Composition on Weight Loss during Caloric Restriction and Subsequent Weight Regain during Refeeding in Aging Mice. <i>Nutrients</i> , 2023, 15, 4836.	4.1	0
599	Metaflammation in obesity and its therapeutic targeting. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	1
600	Obesity and lifespan, a complex tango. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0
601	Seeking satiety: From signals to solutions. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0

#	ARTICLE	IF	CITATIONS
602	Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond. <i>Metabolism: Clinical and Experimental</i> , 2024, 151, 155741.	3.4	1
603	Evidence for the contribution of the gut microbiome to obesity and its reversal. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0
605	Effective Anti-Obesity Drugs Make Losing Weight a Big Deal. <i>Engineering</i> , 2023, , .	6.7	0
606	Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity. <i>Calcified Tissue International</i> , 2024, 114, 86-97.	3.1	1
607	Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. <i>Endocrine Practice</i> , 2024, 30, 160-171.	2.1	3
608	Obesity Management in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 2000.	7.4	8
609	Considerations of delayed gastric emptying with perioperative use of glucagon-like peptide-1 receptor agonists. <i>Medical Journal of Australia</i> , 0, , .	1.7	0
610	Efficacy and safety of semaglutide 2.4%mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year <scp>STEP</scp> 5 trial. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 911-923.	4.4	1
612	Comment on Frampton et al. 2023: Propionate, not acetate, lactate or succinate, may explain carbohydrate effects on satiety. <i>Journal of Physiology</i> , 0, , .	2.9	1
613	Drug Therapies for Diabetes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17147.	4.1	1
615	Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss. <i>Clinical Nutrition</i> , 2024, 43, 246-258.	5.0	0
616	Standardized Assessment of Metabolic Bariatric Surgery Outcomes. <i>JAMA Surgery</i> , 0, , .	4.3	1
617	Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation. <i>Transplantation</i> , 0, , .	1.0	0
618	Obesity and eating disorders: an interactive and complex coexistence. <i>Ijedo</i> , 0, 5, 12.	0.0	0
619	Updates in Bariatric Surgery. <i>American Surgeon</i> , 0, , .	0.8	0
620	SURMOUNTing body weight barriers in type 2 diabetes. <i>Med</i> , 2023, 4, 849-851.	4.4	0
622	Antiobesity pharmacotherapy to facilitate living kidney donation. <i>American Journal of Transplantation</i> , 2024, 24, 328-337.	4.7	0
623	Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2024, 331, 38.	7.4	21



#	ARTICLE	IF	CITATIONS
624	MASLD treatment—a shift in the paradigm is imminent. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
625	3. Prevention or Delay of Diabetes and Associated Comorbidities: <i>Standards of Care in Diabetesâ€”2024</i>. <i>Diabetes Care</i> , 2024, 47, S43-S51.	8.6	1
626	White adipocyte dysfunction and obesity-associated pathologies in humans. <i>Nature Reviews Molecular Cell Biology</i> , 0, , .	37.0	3
627	Treatment and practical considerations of diabetic kidney disease. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
628	Reduction of body weight by increased loading is associated with activation of norepinephrine neurones in the medial nucleus of the solitary tract. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	2.6	1
629	The Impact of Obesity on Inflammatory Bowel Disease. <i>Biomedicines</i> , 2023, 11, 3256.	3.2	3
630	G protein-coupled receptors and obesity. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
631	Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges. <i>Drugs</i> , 2024, 84, 127-148.	10.9	0
632	Tirzepatide. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2023, 36, 9-10.	0.3	0
633	Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 1937-1947.	1.8	0
634	5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: <i>Standards of Care in Diabetesâ€”2024</i>. <i>Diabetes Care</i> , 2024, 47, S77-S110.	8.6	7
635	8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: <i>Standards of Care in Diabetesâ€”2024</i>. <i>Diabetes Care</i> , 2024, 47, S145-S157.	8.6	5
636	A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. <i>Nature Communications</i> , 2023, 14, .	12.8	2
637	Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1008-1015.	4.4	0
638	Effect of Liraglutide on Weight Loss and BMI Among Patients Who Are Overweight and Obese with Type 2 Diabetes: A Systematic Review and Meta-analysis. <i>European Medical Journal (Chelmsford)</i> Tj ETQq0 0 0 rgB8,0 Overlock 10 Tf 50	3.0	0
639	Contemporary Clinical Perspectives on Targeting Remission of Type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
640	A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. <i>Endocrine Practice</i> , 2024, 30, 292-303.	2.1	0
641	Cardioâ€renalâ€metabolic disease in primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 0, , .	4.0	1

#	ARTICLE	IF	CITATIONS
642	Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. <i>Antioxidants</i> , 2024, 13, 16.	5.1	0
643	Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?. <i>Current Heart Failure Reports</i> , 0, , .	3.3	0
644	Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age. <i>Nutrients</i> , 2024, 16, 63.	4.1	0
646	Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes. <i>European Journal of Internal Medicine</i> , 2024, 121, 155-156.	2.2	0
647	Metabolic dysfunction-associated steatotic liver disease and the heart. <i>Hepatology</i> , 0, , .	7.3	1
648	Impact of GLP-1 Agonists on Male Reproductive Healthâ€”A Narrative Review. <i>Medicina (Lithuania)</i> , 2024, 60, 50.	2.0	1
649	Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 0, , .	4.8	0
650	Weight Loss Interventions for Adults With Obesity-Related Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2024, 12, 840-847.	3.8	1
652	Commercially Available Injectables in Diabetes â€” Insulin, Incretins, and More. , 2023, 2, 49-59.		0
653	Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2024, 13, 201.	2.4	1
654	Pharmacotherapy for obesity: moving towards efficacy improvement. <i>Diabetology and Metabolic Syndrome</i> , 2024, 16, , .	2.7	0
655	Weight Loss Following Bariatric Surgery in People with or without Metabolic Syndrome: A 5-Year Observational Comparative Study. <i>Journal of Clinical Medicine</i> , 2024, 13, 256.	2.4	0
656	Enhancing Lifestyles in the Metabolic syndrome (ELM) multisite behavioral efficacy trial. Design and baseline cohort. <i>American Heart Journal</i> , 2024, 270, 136-155.	2.7	0
657	Obesity, Metabolic Syndrome, and Sleep Disorders. , 2023, , 639-658.		0
658	Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. <i>Molecular Metabolism</i> , 2024, 80, 101880.	6.5	1
659	Psychotropic Drugâ€”Related Weight Gain and Its Treatment. <i>American Journal of Psychiatry</i> , 2024, 181, 26-38.	7.2	2
660	Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?. <i>Current Obesity Reports</i> , 2024, 13, 132-140.	8.4	0
661	Review article: Pharmacologic management of obesity â€”updates on approved medications, indications and risks. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 475-491.	3.7	0

#	ARTICLE	IF	CITATIONS
662	Metabolic and Bariatric Surgery in Children: Current Practices and Outcomes. <i>Current Obesity Reports</i> , 2024, 13, 77-86.	8.4	0
663	Glucagon-like Peptide-1 Agonists. <i>JBJS Reviews</i> , 2024, 12, .	2.0	0
664	Recent advances in peptide-based therapies for obesity and type 2 diabetes. <i>Peptides</i> , 2024, 173, 171149.	2.4	1
665	Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. <i>Kaohsiung Journal of Medical Sciences</i> , 2024, 40, 212-220.	1.9	1
666	An RNA-seq atlas of mouse brain areas during fasting and diet-induced obesity. <i>Scientific Data</i> , 2024, 11, .	5.3	0
667	MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges. <i>Cancers</i> , 2024, 16, 259.	3.7	0
668	Chronic Kidney Disease in the Older Adult Patient with Diabetes. <i>Journal of Clinical Medicine</i> , 2024, 13, 348.	2.4	0
669	Gastrointestinal hormones: History, biology, and measurement. <i>Advances in Clinical Chemistry</i> , 2024, , 111-154.	3.7	0
670	Integrating Pharmacotherapy and Psychotherapy for Weight Loss. <i>Journal of Health Service Psychology</i> , 2023, 49, 177-184.	1.3	1
672	Will obesity break your heart - cardiac biomarkers in the Japan Morning Surge-Home Blood Pressure study. <i>Hypertension Research</i> , 2024, 47, 808-810.	2.7	0
674	The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 17, 227-230.	2.4	0
675	Net prices of new antiobesity medications. <i>Obesity</i> , 2024, 32, 472-475.	3.0	0
676	Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1150-1156.	4.4	1
678	Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. <i>Current Problems in Cardiology</i> , 2024, 49, 102403.	2.4	0
679	Adaptive infusion of a glucagon-like peptide-1/glucagon receptor coagonist <sc>G3215</sc>, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1479-1491.	4.4	0
681	Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
683	2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. <i>Circulation</i> , 2024, 149, .	1.6	8
684	Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond. <i>Expert Review of Clinical Pharmacology</i> , 2024, 17, 235-246.	3.1	0

#	ARTICLE	IF	CITATIONS
685	Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment. <i>Children</i> , 2024, 11, 153.	1.5	0
686	The critical role of abdominal obesity as a crucial cardiovascular risk factor. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1967-1970.	4.4	0
687	Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. <i>British Journal of Anaesthesia</i> , 2024, 132, 644-648.	3.4	0
689	Public health perspective on new weight loss medications. <i>BMJ, The</i> , 0, , q196.	6.0	1
690	Gut Hormones and Metabolic Syndrome. , 2023, , 357-372.		0
691	Stem Cell Theory of Cancer: Clinical Implications for Cellular Metabolism and Anti-Cancer Metabolomics. <i>Cancers</i> , 2024, 16, 624.	3.7	0
693	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0
694	The effect of bariatric surgery type on cardiac reverse remodelling. <i>International Journal of Obesity</i> , 0, , .	3.4	0
695	Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. <i>Frontiers in Public Health</i> , 0, 12, .	2.7	1
696	Is Tirzepatide the New Game Changer in Type 2 Diabetes?. <i>Endocrines</i> , 2024, 5, 72-86.	1.0	0
697	What is the pipeline for future medications for obesity?. <i>International Journal of Obesity</i> , 0, , .	3.4	1
698	Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management. <i>Clinical Therapeutics</i> , 2024, 46, 289-292.	2.5	0
699	Pharmacological interventions in human aging. <i>Ageing Research Reviews</i> , 2024, 95, 102213.	10.9	0
700	Tirzepatide, a dual incretin analog, is a boon in metabolic syndrome: an editorial. <i>Annals of Medicine and Surgery</i> , 2024, 86, 1249-1250.	1.1	0
702	Obesity and Overweight: The "Elephant in the Room" That We can No Longer Ignore: Time to SELECT Treatments. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2024, 31, 3-6.	2.2	0
703	Treat Obesity to Treat Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2024, 15, 611-622.	2.5	0
704	Obesity and the kidney: mechanistic links and therapeutic advances. <i>Nature Reviews Endocrinology</i> , 0, , .	9.6	0
705	Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention. <i>European Heart Journal</i> , 2024, 45, 1392-1394.	2.2	0

#	ARTICLE	IF	CITATIONS
706	Abdominal donor-site complications following autologous breast reconstruction: A multi-institutional multisurgeon study. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2024, 90, 88-94.	1.0	0
707	Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years. <i>Journal of the American College of Cardiology</i> , 2024, 83, 637-648.	2.8	2
708	Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index $\geq 27$ kg/m <sup>2</sup> : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. <i>Hypertension</i> , 2024, 81, .	2.7	1
709	Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2024, 12, 162-173.	11.4	3
710	A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. <i>Nature Metabolism</i> , 2024, 6, 290-303.	11.9	2
711	Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice. <i>Clinical Science</i> , 2024, 138, 173-187.	4.3	0
712	The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1882.	4.1	0
713	Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. <i>Journal of Diabetes Science and Technology</i> , 0, .	2.2	0
714	Redefining peptide therapeutics with semaglutide. <i>Nature Chemistry</i> , 2024, 16, 296-296.	13.6	0
715	Sarcopenic obesity in older adults: a clinical overview. <i>Nature Reviews Endocrinology</i> , 2024, 20, 261-277.	9.6	0
716	Current and future state of pharmacological management of pediatric obesity. <i>International Journal of Obesity</i> , 0, .	3.4	0
717	Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States. <i>Cancers</i> , 2024, 16, 684.	3.7	0
718	GLP1R (glucagon-like-peptide-1 incretin receptor), diabetes and obesity phenotypes: An in silico approach revealed new pathogenic variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2024, 18, 102956.	3.6	1
719	The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. <i>Patient Preference and Adherence</i> , 0, Volume 18, 373-382.	1.8	1
720	Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
721	Projected impact of anti-obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity. <i>Pediatric Obesity</i> , 2024, 19, .	2.8	0
722	Effects of dietary fibre on metabolic health and obesity. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2024, 21, 301-318.	17.8	0
723	Sexual function and correlates among adults aged 50+ years in China: Findings from the sexual well-being (<sc>SWELL</sc>) study. <i>Journal of the American Geriatrics Society</i> , 2024, 72, 1122-1135.	2.6	0

#	ARTICLE	IF	CITATIONS
724	Obesity management: sex-specific considerations. Archives of Gynecology and Obstetrics, 2024, 309, 1745-1752.	1.7	0
725	Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine, 2024, 68, 102429.	7.1	0
726	Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial. Lancet Regional Health - Europe, The, 2024, 39, 100853.	5.6	0
727	G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?. Biomedicine and Pharmacotherapy, 2024, 172, 116245.	5.6	0
728	Isomaltulose Enhances GLP-1 and PYY Secretion to a Mixed Meal in People With or Without Type 2 Diabetes as Compared to Saccharose. Molecular Nutrition and Food Research, 2024, 68, .	3.3	0
730	What is the evidence regarding the safety of new obesity pharmacotherapies. International Journal of Obesity, 0, , .	3.4	0
731	Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease. Internal Medicine, 2024, , .	0.7	0
732	Drug approach to treatment for obesity in adults: perspectives and considerations. Revista Espanola De Enfermedades Digestivas, 2024, 116, .	0.3	0
733	The association of weight loss from anti-obesity medications or bariatric surgery and apnea-hypopnea index in obstructive sleep apnea. Obesity Reviews, 2024, 25, .	6.5	0
734	Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease. Diabetes, Obesity and Metabolism, 2024, 26, 3-12.	4.4	0
735	Methodological Insights and Future Directions in Gut Hormone Studies after Bariatric Metabolic Surgery: A Scoping Review. , 0, , .		0
736	The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinology and Metabolism, 2024, 39, 12-22.	3.0	0
737	The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. Clinical Gastroenterology and Hepatology, 2024, , .	4.4	0
738	Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies. Diabetes Spectrum, 2024, 37, 48-58.	1.0	4
739	Weight Loss Treatment and Longitudinal Weight Change Among Primary Care Patients With Obesity. JAMA Network Open, 2024, 7, e2356183.	5.9	0
740	Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?. Gastrointestinal Disorders, 2024, 6, 180-190.	0.8	0
741	Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians. , 2024, 38, 31-35.		0
742	Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 2024, 69, 102475.	7.1	0

#	ARTICLE	IF	CITATIONS
743	Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer. <i>JACC: CardioOncology</i> , 2024, 6, 16-32.	4.0	0
744	Trends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study. <i>Diabetes Therapy</i> , 2024, 15, 801-817.	2.5	0
746	Clinical Trial on and Regulatory Considerations for Herbal Medicines for Lifestyle Diseases. , 2023, , 573-595.		0
747	Targeting the Natriuretic Peptide System to Improve Outcomes. <i>Journal of the American College of Cardiology</i> , 2024, 83, 915-917.	2.8	0
748	Assessment and Management of Patients with Obesity and Hypertension in European Society of Hypertension Excellence Centres. A survey from the ESH Working Group on Diabetes and Metabolic Risk Factors.. <i>Blood Pressure</i> , 2024, 33, .	1.5	0
749	Contemporary Treatments for Obesity: Physical Activity in the Context of Antiobesity Medications. <i>Translational Journal of the American College of Sports Medicine</i> , 2024, 9, .	0.6	0
750	Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2024, 19, e0297488.	2.5	0
751	Impact of Glucagon-Like Peptide-1 Agonist Deprescription in Type-2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study. <i>Diabetes Therapy</i> , 2024, 15, 843-853.	2.5	0
752	Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management. <i>Cell Metabolism</i> , 2024, 36, 670-683.	16.2	0
753	Obstructive sleep apnoea in obesity: A review. <i>Clinical Obesity</i> , 0, , .	2.0	0
754	Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment. <i>Science Advances</i> , 2024, 10, .	10.3	0
755	Unraveling Adipose Tissue Dysfunction: Molecular Mechanisms, Novel Biomarkers, and Therapeutic Targets for Liver Fat Deposition. <i>Cells</i> , 2024, 13, 380.	4.1	0
756	Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study. <i>Obesity Surgery</i> , 2024, 34, 1324-1332.	2.1	0
758	Obesity, NAFLD/NASH, and Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2024, 26, S-231-S-240.	4.4	0
759	Weight-centric prevention of cancer. , 2024, 10, 100106.		0
760	The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Discovery</i> , 2024, 19, 511-522.	5.0	0
762	Obesity and Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2024, 132, 232-239.	1.2	0
763	Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn. <i>International Journal of Obesity</i> , 0, , .	3.4	0

#	ARTICLE	IF	CITATIONS
764	Age-related disease: Eyes. , 2024, , 195-204.		0
765	Acidosis and aspiration: Popular diabetes medications and the risks they pose in the perioperative period. Journal of Clinical Anesthesia, 2024, 95, 111416.	1.6	0
766	Update on Endoscopic Treatments for Obesity. Current Obesity Reports, 0, , .	8.4	0
767	An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update. Expert Review of Clinical Pharmacology, 2024, 17, 349-362.	3.1	0
768	Relationship between body mass index and cardiometabolic health in a multi-ethnic population: A project baseline health study. American Journal of Preventive Cardiology, 2024, 18, 100646.	3.0	0
769	Intestinal Acyl-CoA synthetase 5 (ACSL5) deficiency potentiates postprandial GLP-1 & PYY secretion, reduces food intake, and protects against diet-induced obesity. Molecular Metabolism, 2024, 83, 101918.	6.5	0
770	Obesity: the perfect storm for heart failure. ESC Heart Failure, 0, , .	3.1	0
771	Glucagon-like peptide-1 analogs: Miracle drugs are blooming?. European Journal of Medicinal Chemistry, 2024, 269, 116342.	5.5	0
772	Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice. Drug Design, Development and Therapy, 0, Volume 18, 845-858.	4.3	0
773	Attitudes and knowledge about weight management among primary care physicians in Israel: a cross-sectional study. , 2024, 25, .		0
775	A New Epoch in Treating Diseases of the Heart. Journal of Clinical Lipidology, 2024, 18, e5-e9.	1.5	0
777	Current and Future Treatments of Vascular Cognitive Impairment. Stroke, 2024, 55, 822-839.	2.0	0
778	Efficacy and safety of tirzepatide, <sc>GLP</sc>-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity, 2024, 32, 840-856.	3.0	0
779	A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues. Journal of Medicinal Chemistry, 2024, 67, 4998-5010.	6.4	0
780	Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews, 2024, 25, .	6.5	0
781	Approach to Obesity Treatment in Primary Care. JAMA Internal Medicine, 0, , .	5.1	0
784	Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome, and Pulmonary Hypertension. Sleep Medicine Clinics, 2024, 19, 307-325.	2.6	0
785	b. Part II: Early Vascular Aging and Obesity Treatment. , 2024, , 447-454.		0



#	ARTICLE	IF	CITATIONS
787	CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovascular Diabetology, 2024, 23, .	6.8	0
788	The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis. Diabetes, Obesity and Metabolism, 2024, 26, 2001-2016.	4.4	0
790	Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technology and Therapeutics, 0, , .	4.4	0
791	Practical strategies to manage obesity in type 2 diabetes. Diabetes, Obesity and Metabolism, 2024, 26, 2029-2045.	4.4	0
792	Next Generation Weight Loss Drugs for the Prevention of Cancer?. Cancer Control, 2024, 31, .	1.8	0
793	Effectiveness and safety of drugs for obesity. BMJ, The, 0, , e072686.	6.0	0
794	The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 17, 701-714.	2.4	0
796	Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. , 2024, 10, 100108.		0
797	The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective. Journal of Clinical Medicine, 2024, 13, 1617.	2.4	0
798	Triglyceride-glucose index: A promising biomarker for predicting risks of adverse pregnancy outcomes in Hangzhou, China. Preventive Medicine Reports, 2024, 41, 102683.	1.8	0
799	Gut hormones and appetite regulation. Current Opinion in Endocrinology, Diabetes and Obesity, 2024, 31, 115-121.	2.3	0